ArticleOncology letters2019

Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.

Marcelo Bonomi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.